What are the possible side effects of using ruxolitinib tablets/ruxolitinib?

Ruxolitinib tablets/ruxolitinib (JAKAVI) is an oral JAK1/2 inhibitor, mainly used to treat myeloproliferative diseases, such as polycythemia vera (PV) andmyelofibrosis (MF). The drug inhibits the JAK-STAT signaling pathway and blocks abnormal cytokine activity, thereby alleviating disease symptoms and delaying disease progression. Although JAKAVI has shown good effects in improving symptoms such as spleen enlargement and relieving fatigue and itching, it may also cause some side effects during the treatment process. These adverse reactions are important content that patients must understand before taking the drug.

The most common side effects focus on the blood system, especially anemia and thrombocytopenia. Because ruxolitinib inhibits bone marrow hematopoietic function, some patients may experience a decrease in hemoglobin or platelet count in the early stages of treatment. For patients with a history of anemia, blood routine monitoring may be required and drug dosage may be adjusted according to the actual situation. In addition, some patients may also experience neutropenia, which will increase the risk of infection and requires timely intervention measures combined with changes in white blood cell numbers.

Among infection-related adverse reactions, upper respiratory tract infection, recurrence of herpes zoster, and urinary tract infection are relatively common. After the immune system is suppressed to a certain extent, the risk of reactivation of latent viruses increases, and special attention should be paid to patients taking JAKAVI for a long time. In terms of skin, some patients may experience symptoms such as rash, itching, and dryness; gastrointestinal reactions such as diarrhea, nausea, and loss of appetite have also been reported in individual cases, but are usually mild.

In addition, there are also studies suggesting thatJAKAVI may cause an increase in liver function indicators or changes in blood lipids in a small number of people. Therefore, long-term users need to regularly monitor liver and kidney function and metabolic indicators. In terms of mental health, some patients report experiencing increased fatigue or mild dizziness during medication, but most of these are transient.

Reference materials:https://www.jakavi.com/